UCSF spinout Siolta Therapeutics picked up SymBiosis and Kirin Holdings in a round set to fund efficacy trials of its potential asthma treatment.
Siolta Therapeutics, a US-based microbe therapy spinout of University of California, San Francisco, has attracted $30m in a series B round involving medical services provider SymBiosis.
Kirin Health Innovation Fund, a corporate venturing vehicle for food and healthcare products group Kirin Holdings, also participated, as did Seventure’s Health for Life Capital Fund, Global Brain’s GB-VII and private investor Marc Benioff.
Founded in 2016, Siolta Therapeutics hopes to uncover therapeutic microbes capable of treating chronic inflammatory diseases such as…